Researchers have characterized common adverse reactions to combination lenvatinib and pembrolizumab in patients with advanced renal cell carcinoma.
A survey of US urologic oncologists suggests that reproductive organ-sparing and nerve-sparing radical cystectomy may be underused in women with bladder cancer.
Adding interferon alfa to treatment with temozolomide and radiotherapy prolongs survival in patients with newly diagnosed, high grade glioma, a phase 3 trial suggests.
US medical oncologists may lack understanding of biosimilars and have limited access to education about these products, a survey suggests.
Combination avelumab and axitinib has shown long-term activity in previously untreated patients with advanced renal cell carcinoma.
The COVID-19 pandemic has hindered the early diagnosis and treatment of cancer, and this may have set back cancer outcomes by almost a decade in Europe, a new report suggests.
In the absence of immunosuppression, systemic cancer therapies do not increase the risk of severe COVID-19 or cytokine storm, a study suggests.
Adjuvant atezolizumab can prevent recurrence and death, thereby reducing costs, in patients with early non-small cell lung cancer, a study suggests.
Patients with mHSPC who receive enzalutamide plus ADT are 4 times more likely to achieve undetectable PSA levels than patients who receive ADT alone, according to an analysis of data from the ARCHES trial.
Real-world data support first-line palbociclib plus an aromatase inhibitor as standard care for HR+, HER2- metastatic breast cancer, according to researchers.
